Towards prediction and modulation of treatment response

Radiotherapy and Oncology

Volumn 50, Issue 1, 1999, Pages 1-11

  Bartelink, Harry ^a   Begg, Adrian ^a   Martin, José Coco ^a   Van Dijk, Mariska ^a   Van 't Veer, Laura ^a   Van der Vaart, Paul ^a   Verheij, Marcel ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Apoptosis; Biological assays; Cisplatin DNA adducts; Estrogen receptor; Translational research; Treatment tailoring

Indexed keywords

CISPLATIN;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER SURVIVAL; DNA ADDUCT; DNA DETERMINATION; DOSE RESPONSE; DRUG DNA BINDING; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; PRIORITY JOURNAL; RADIATION DOSE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHROMOSOME ABERRATIONS; CISPLATIN; DNA ADDUCTS; DOSE FRACTIONATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; NEOPLASMS; RADIOTHERAPY DOSAGE; RECEPTORS, ESTROGEN; REMISSION INDUCTION; SIGNAL TRANSDUCTION; SURVIVAL RATE;

EID: 0032978914     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(99)00009-2     Document Type: Article

References (52)

1. Ang KK, Trotti A, Garden AS, et al. Overall time factor in postoperative radiation: Results of a prospective randomized trial (abstract 108). Radiother. Oncol. 1996; 40 (Suppl.1): S30.
2. Bartelink H, Batterman J, Hart G. Half body irradiation. Int. J. Radiat. Biol. Phys. 1980; 6: 87-90.
3. Bartelink HB, Kallman RF, Rapacchietta D, Hart GAM. Therapeutic enhancement in mice by clinically relevant dose and fractionation schedules of CDDP and irradiation. Radiother. Oncol. 1986; 6: 61-74.
4. Bartelink H, Rubens RD, Van der Schueren E, Sylvester R. Hormonal therapy prolongs survival in irradiated locally advanced breast cancer: A European organization for research and treatment of cancer randomized phase III trial. J. Clin. Oncol. 1997; 15: 207-215.
5. Barton MB, Keane TJ, Gadalla T. The effect of treatment time on tumor control in the radical radiotherapy of laryngeal cancer. Radiother. Oncol. 1992; 23: 137-143.
6. Begg AC, McNally NJ, Shrieve DC, Karcher H. A method to measure the duration of DNA synthesis and the potential doubling time from a single sample. Cytometry 1985; 6: 620-626.
7. Begg AC, Hofland K, van Glabbeke M, Bartelink H, Horiot JC. Predictive value of potential doubling time for radiotherapy of head and neck tumour patients: Results from the EORTC cooperative trial 22851. Semin. Radiat. Oncol. 1992; 1: 22-25.
8. Begg AC, Haustermans K, Hart AAM, et al. The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer: A multicenter analysis. Radiat. Oncol 1998; in press.
9. Begg AC. Cisplatin and radiation: Interaction probabilities and therapeutic possibilities. Int. J. Radiat. Oncol. Biol. Phys. 1990; 19: 1183- 1189.
10. Blommaert FA, Michael C, Terheggen PMAB, et al. Drug induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: Inter-individual variation and correlation with disease response. Cancer Res. 1993; 53: 5669-5675.
11. Bourhis J, Pignon JP, Designé M, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): (1) loco-regional treatment vs. same treatment + chemotherapy (CT). Proceedings 34th ASCO, May 16-19, Los Angeles, USA (abstract 1487). J. Clin. Oncol. 1998; 17: 386a.
12. Calais G, Alfonsi M, Bardet E, et al. Randomized study comparing radiation alone (RT) versus RT with concomitant chemotherapy (CT) in stages III and IV oropharynx carcinoma (ARCORO). Preliminary results of the 94-01 study from the French group of radiation oncology for head and neck cancer (GORTEC). Proceedings 34th ASCO, May 16-19, Los Angeles, USA (abstract 1484). J. Clin. Oncol. 1968; 17: 385a.
13. Chen Y-R, Wang X, Templeton D, Davis RJ, Tan T-H. The role of c- Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and radiation. J. Biol. Chem. 1996; 271: 31929-31936.
14. Coco Martin JM, Begg AC. Detection of radiation-induced chromosome aberrations using fluorescence in situ hybridization in drug- induced premature chromosome condensations of tumor cell lines with different radiosensitivities. Int. J. Radiat. Biol. 1997; 71: 265-73.
15. Cummings BJ, Keane TJ, Pintillie M, et al. A prospective randomized trial of hyperfractionated versus conventional once daily radiation for advanced squamous cell carcinomas of the larynx and pharynx (abstract 107). Radiother. Oncol. 1996; 40 (Suppl. 1): S30.
16. Dewey WC, Ling CC, Meyn RE. Radiation-induced apoptosis: Relevance to radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 1995; 33: 781- 796.
17. Dubray B, Breton C, Delic J, et al. In vitro radiation-induced apoptosis and early response to low-dose radiotherapy in non-Hodgkin's lymphomas. Radiother. Oncol. 1998; 46: 185-191.
18. Early Breast Cancer Trialists' Collaborative Group, 1998, Tamoxfen for early breast cancer: An overview of the randomized trials (9114), Lancet, 351: 1451-1467.
19. Fyles A, Keane TJ, Barton M, Simm J. The effect of overall treatment duration in the local control of cervix cancer. Radiother. Oncol. 1992; 25: 273-279.
20. Haimovitz-Friedman A, Kan C-C, Ehleiter D, et al. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J. Exp. Med. 1994; 180: 525-535.
21. Hannun YA. The sphingomyelin cycle and the second messenger function of ceramide. J. Biol. Chem 1994; 269: 3125-3128.
22. Horiot JC, Bontemps P, Van den Bogaert W, et al. Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers: Results of the EORTC 22851 randomized trial. Radiother. Oncol. 1997; 44: 111-121.
23. Horiot JC, Le Fur R, Nguyen T, et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy. Radiat Oncol. 1992; 25: 231-241.
24. Jarvis WD, Kolesnick RN, Fornari FA, Traylor RS, Gewirtz DA, Grant S. Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway. Proc. Natl. Acad. Sci. USA 1994; 91: 73-77.
25. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: A randomized study. J. Clin. Oncol. 1997; 15: 893-900.
26. Kasid U, Suy S, Dent P, Ray S, Whiteside TL, Sturgill TW. Activation of raf by ionizing radiation. Nature 1996; 382: 813-816.
27. Kolesnick R. Sphingomyelin and derivatives as cellular signals. Prog. Lipid Res. 1991; 30: 1-38.
28. Lelieveld P, Scoles MA, Brown JM, Kallman RF. The effect of treatment in fractionated schedules with the combination of X-irradiation and six cytotoxic drug on the RIF-1 tumor and normal mouse skin. Int. J. Radiat. Oncol. Biol. Phys. 1985; 11: 111-121.
29. Ling CC, Chen CH, Li WX. Apoptosis induced at different dose rates: Implication for the shoulder region of cell survival curves. Radiother. Oncol. 1994; 32: 129-136.
30. Meyn RE, Stephens LC, Hunter NR, Ang KK, Milas L. Reemergence of apoptotic cells between fractionated doses in irradiated murine tumors. Int. J. Radiat. Oncol. Biol. Phys. 1994; 30: 619-624.
31. Meyn RE, Stephens LC, Ang KK, Hunter N, Milas L, Peters LJ. Heterogeneity in apoptosis development in irradiated murine tumors. Int. J. Radiat. Biol. 1993; 64: 583-591.
32. Naja A, Roché H, Mihura J, et al. Castration and tamoxifen versus chemotherapy (FAC) for premenopausal, node and receptors positive breast cancer patients: A randomized trial with a 7 years median follow up (abstract 87). Radiother. Oncol. 1997; 43 (Suppl. 2): S22.
33. Overgaard J, Hjelm-Hansen M, Vendelbo Johansen L, Andersen AP. Comparison of conventional and split course radiotherapy as primary treatment in carcinoma of the larynx. Acta Oncol. 1988; 27: 147-152.
34. Overgaard J, Sand Hansen H, Overgaard M, et al. Importance of overall treatment time for the outcome of radiotherapy in head and neck carcinoma. Experience from the Danish head and heck cancer study. In: Kogelnik HD, Sedlmayer F, et al., editors. Progress in Radiooncology. Proceedings of the 6th International Meeting, Salzburg, Austria, May 13-17, Bologna: Monduzzi Editore, 1998. pp. 743.
35. Quintans J, Kilkus J, McShan CL, Gottschalk AR, Dawson G. Ceramide mediates the apoptotic response of WEHI 231 cells to anti- immunoglobulin, corticosteroids and irradiation. Biochem. Biophys. Res. Commun. 1994; 202: 710-714.
36. Rose P, Bundy B, Thigpen J, et al. Significant preliminary results of a phase III randomized study of concomitant chemotherapy with weekly cisplatin vs. hydroxyurea, 5-fluorouracil infusion and bolus cisplatin vs. hydroxyurea in advanced cervical cancer: A gynecologic oncology group (GOG) study. Proceedings 34th ASCO, May 16-19, Los Angeles, USA (abstract 1391). J. Clin. Oncol. 1998; 17: 360a.
37. Santana P, Penã LA, Haimovitz-Friedman A, et al. Acid sphingomyelinase-deficient human lymphoblasts and mice are defective in radiation-induced apoptosis. Cell 1996; 86: 189-99.
38. Saunders M, Dische S, Barrett A, Harvey A, Gibson D, Parmar M. Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: A randomized multicentre trial. Lancet 1997; 350: 161-165.
39. Sawai H, Okazaki T, Yamamoto H, et al. Requirement of AP-1 for ceramide-induced apoptosis in human leukemia HL-60 cells. J. Biol. Chem. 1995; 270: 27326-27331.
40. Schaake-Koning C, Van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N. Engl. J. Med. 1992; 326: 524-530.
41. Schuster-Uitterhoeve ALJ, Van de Vaart PJM, Schaake-Koning CCE, et al. Feasibility of escalating daily doses of cisplatin in combination with accelerated radiotherapy in non-small cell lung cancer. Eur. J. Cancer 1996; 32A: 1314-1319.
42. Scottish Cancer Trials Breast Group and ICRF Breast Unit, Guy's Hospital, London, 1993, Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: The Scottish trial, Lancet, 341: 1293-1298.
43. Shirakabe K, Yamaguchi K, Shibuya H, et al. TAK1 mediates the ceramide signaling to stress-activated protein kinase/c-Jun N-terminal kinase. J. Biol. Chem. 1997; 272: 8141-8144.
44. Stephens LC, Ang KK, Schultheiss TE, Milas L, Meyn RE. Apoptosis in irradiated murine tumors. Radiat. Res 1991; 127: 308-316.
45. Ten Bokkel Huinink WW, Schornagel JH, Hilton A, Somers R, Bartelink H. Topical application of miltefosine against skin metastases of breast cancer. Proceedings of ASCO, San Diego, USA, May 17-19 (abstract 39). J. Clin. Oncol. 1992; 11: 53.
46. Terheggen PMAB, Emondt JY, Floot BGJ, et al. The correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum. Cancer Res. 1990; 50: 3556-3561.
47. Van Dijk MAJ, Floore AN, Kloppenborg KIM, Van 't Veer LJ. A functional assay in yeast for human estrogen receptor displays wild-type and variant estrogen receptor messenger rnas present in breast carcinoma. Cancer Res. 1997; 57: 3478-3485.
48. Verheij M, Bose R, Lin XH. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 1996; 380: 75-79.
49. Verheij M, Ruiter GA, Zerp SF, et al. The role of the stress-activated protein kinase (SAPK/JNK) signaling pathway in radiation-induced apoptosis. Radiother. Oncol. 1998; 47: 225-232.
50. Verheij M, van Blitterswijk WJ, Bartelink H. Radiation-induced apoptosis: The ceramide-sapk signaling pathway and clinical aspects. Acta Oncol. 1998; in press.
51. West CM, Davidson SE, Roberts SA, Hunter RD. The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix. Br. J. Cancer 1997; 76: 1184-1190.
52. Zanke BW, Boudreau K, Rubie E, et al. The stress-activated protein kinase pathway mediates cell death following injury induced by cis-platinum, UV irradiation or heat. Curr. Biol 1996; 6: 606-613.